Prothena reported $3.74M in Interest Income for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Income Change
Acadia Pharmaceuticals ACAD:US USD 3.63M 1.34M
Agios Pharmaceuticals AGIO:US USD 6.49M 2.67M
Alnylam Pharmaceuticals ALNY:US USD 14.08M 6.26M
Biogen BIIB:US USD 49.9M 26M
BioMarin Pharmaceutical BMRN:US USD 8.71M 3.71M
Bluebird Bio BLUE:US USD 383K 209K
Exelixis EXEL:US USD 16.99M 7.49M
Intra Cellular Therapies ITCI:US USD 3.39M 1.26M
Nektar Therapeutics NKTR:US USD 3.13M 1.08M
Prothena PRTA:US USD 3.74M 1.83M
Ultragenyx Pharmaceutical RARE:US USD 6.2M 2.72M
Vertex Pharmaceuticals VRTX:US USD 86M 39.8M
Vital Therapies VTL:US USD 698K 468K